Extractables study design determines which chemical compounds a packaging material, medical device, or drug container can release under controlled extraction conditions โ and how to measure them reliably. A well-structured extractables study design forms the scientific foundation for leachables risk assessment, regulatory submission, and patient safety evaluation across pharmaceutical, biotech, and medical device programs.
Regulatory agencies including the FDA and EMA expect sponsors to demonstrate that container-closure systems and device materials do not introduce harmful chemicals into drug products or patients. Consequently, the quality of your extractables study design directly influences approval timelines and post-market safety commitments. Teams at Materials Metric work with clients across these industries to build studies that satisfy both scientific rigor and regulatory expectations.
Furthermore, the field has grown more complex as combination products, novel polymers, and biologic drug formulations multiply. In particular, biologics are sensitive to trace-level extractables that can trigger protein aggregation or immunogenic responses. Therefore, study design must account for material composition, drug product type, route of administration, and intended patient population โ all before a single extraction begins.
Key Takeaways
- Extractables study design is the systematic plan for identifying and quantifying chemicals that migrate from materials under exaggerated extraction conditions.
- Study scope, solvent selection, extraction conditions, and analytical methods must align with regulatory guidance such as ISO 10993-18 Chemical Characterization.
- Analytical technique selection โ including GC-MS Analysis, HPLC Analysis, and elemental analysis โ determines the breadth of the chemical profile generated.
- Threshold-based risk frameworks, including Analytical Evaluation Thresholds (AET), guide which compounds require full toxicological evaluation.
- Early-stage material screening can prevent costly late-stage reformulation or regulatory delays.
- Method development and validation are inseparable from study design quality.
Extractables Study Design: a structured experimental plan that defines the materials to be tested, extraction solvents and conditions, analytical methods, acceptance criteria, and reporting framework used to identify and quantify all chemicals that a material can release under controlled, exaggerated conditions โ prior to leachables assessment and regulatory submission.
Key fact: Extractables identified during container-closure or device characterization studies represent one of the leading root causes of late-stage drug product failures and regulatory deficiency letters in pharmaceutical development programs.
What Is Extractables Study Design and Why Does It Matter?
An extractables study design is the master plan that governs every scientific decision made before, during, and after an extraction experiment. It specifies which materials to test, what solvents to use, how long to extract, which analytical platforms to deploy, and what thresholds to apply. Without this plan, data gaps emerge โ and regulators ask pointed questions during review.
Moreover, a poorly scoped study can miss whole chemical classes. For example, a study relying only on GC-MS Analysis may detect volatile and semi-volatile organics effectively but overlook non-volatile species, inorganic elements, or oligomers. Consequently, comprehensive study design demands multiple orthogonal analytical techniques working in parallel.
The Regulatory Landscape Driving Study Design Requirements
Several regulatory frameworks shape what a compliant extractables study design must include. The ISO 10993-18 Chemical Characterization standard provides detailed guidance for medical devices, covering material characterization, extraction conditions, and analytical evaluation thresholds. Meanwhile, ICH Q3E (anticipated guidance on extractables and leachables) and USP chapters such as USP General Chapter <232> Elemental Impurities guide pharmaceutical applications.
These frameworks share a common thread: the study must be designed to detect potential hazards at or below toxicologically relevant thresholds. Importantly, the analytical evaluation threshold (AET) is derived from the permitted daily exposure (PDE) and the daily dose of the product. Therefore, knowing the clinical use scenario before designing the study is non-negotiable.
How Study Design Connects to Patient Safety
Extractables data feeds directly into the safety risk assessment. Specifically, each identified compound undergoes toxicological evaluation to determine whether it poses a risk at expected exposure levels. Furthermore, the study design determines whether that toxicological picture is complete or has blind spots.
For biologic products, even trace quantities of extractables can cause product instability or immunogenicity. As a result, study design for biologics typically demands lower detection limits, broader solvent coverage, and more sensitive analytical methods than studies for small-molecule drugs. The Biocompatibility & Toxicity Testing framework integrates tightly with extractables findings to complete the risk picture.
How to Define the Scope of an Extractables Study Design
Scope definition is the single most consequential step in extractables study design. It answers: what gets tested, under what conditions, and to what analytical depth? Misjudging scope โ either too narrow or unnecessarily broad โ wastes resources and creates regulatory risk.
Notably, scope depends on the material’s function, the drug product’s route of administration, the patient population, and the duration of patient contact. For instance, a primary container in direct contact with an injectable biologic demands more exhaustive characterization than a secondary packaging component with no drug contact.
Defining Material and Component Boundaries
The first scoping decision involves identifying which materials and components to include. Container-closure systems may consist of multiple components: vials, stoppers, plungers, caps, and adhesive labels. Each component contributes its own chemical inventory. Therefore, teams must decide whether to test components individually, as assembled systems, or both.
In addition, medical device extractables and leachables programs face similar decisions for multi-material device assemblies. Tubing sets, films, adhesives, and coatings each require separate consideration. Our article on extractables vs leachables explains the key conceptual distinction that guides component selection.
Selecting Appropriate Extraction Solvents
Solvent selection critically influences which extractables a study will detect. Regulatory guidance recommends using solvents that represent the range of drug product polarity โ typically aqueous, organic, and acidic or basic media. Furthermore, solvents should be chosen to maximize extraction efficiency, not just mimic the drug product matrix.
Common solvent systems include water, isopropyl alcohol (IPA), hexane, methanol, and simulated drug product formulations. However, for parenteral or ophthalmic products, physiologically relevant extracting media (such as saline or phosphate-buffered saline) may also apply. As a result, many studies run three to five solvent systems in parallel to capture the full chemical profile. The extraction conditions article on our site explores this topic in greater depth.
Setting Extraction Time and Temperature Parameters
Extraction conditions are deliberately exaggerated beyond real-use scenarios. This exaggeration ensures the study identifies the worst-case chemical inventory โ not just what leaches under normal storage. Specifically, accelerated conditions such as elevated temperature (e.g., 40ยฐC or 70ยฐC) and extended contact time push extractables levels well above those expected in actual product contact.
Moreover, exhaustive extraction approaches use reflux or repeated extractions until extractable levels plateau, ensuring that the study captures essentially all mobile chemical species. The choice between exaggerated and exhaustive extraction depends on the regulatory pathway, product type, and risk level assigned to the material.
Which Analytical Methods Should an Extractables Study Design Include?
Analytical method selection defines the chemical classes your study can detect and quantify. No single technique covers all possible extractables. Therefore, extractables study design routinely combines multiple complementary platforms to achieve broad chemical coverage.
Furthermore, the chosen methods must be sensitive enough to detect analytes at or below the AET. Method development and validation must precede sample analysis โ an often underestimated workload in study planning. The team at Method Development & Validation can establish fit-for-purpose methods tailored to your specific material and product type.
Chromatographic Techniques for Organic Extractables
Gas chromatographyโmass spectrometry remains the primary tool for volatile and semi-volatile organic extractables. GC-MS Analysis provides excellent sensitivity and library-based compound identification for compounds such as antioxidants, plasticizers, monomers, and processing aids. Headspace GC-MS additionally captures highly volatile species that would otherwise evaporate during sample preparation.
For non-volatile and polar compounds, HPLC Analysis coupled with UV, fluorescence, or mass spectrometric detection is the preferred approach. In particular, LC-MS/MS delivers high sensitivity for oligomers, surfactants, UV stabilizers, and other polar extractables that GC-MS cannot efficiently analyze. Together, GC-MS and LC-MS provide the core organic extractables profile in most regulatory submissions.
Spectroscopic Techniques for Structural Confirmation
Chromatography separates and quantifies compounds, but spectroscopic tools confirm their identity and structure. FTIR Analysis rapidly identifies functional groups and polymer classes in bulk material characterization. Meanwhile, NMR Spectroscopy provides definitive structural elucidation for unknown extractables that mass spectral library matching cannot fully resolve.
In addition, Raman Spectroscopy complements FTIR analysis for materials that absorb strongly in the infrared range, such as aqueous solutions or black-pigmented polymers. Consequently, the combination of chromatographic separation and spectroscopic confirmation builds a defensible identification record for each detected compound.
Elemental Analysis for Inorganic Extractables
Inorganic extractables โ including heavy metals and catalyst residues โ require dedicated elemental analysis platforms. Specifically, inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma optical emission spectrometry (ICP-OES) deliver the sub-ppb detection limits required for compliance with USP General Chapter <232> Elemental Impurities and ICH Q3D.
Furthermore, XRF Analysis serves as a rapid bulk-screening tool to flag materials with high concentrations of elements of concern before solution-based ICP analysis. Meanwhile, XPS Analysis characterizes surface elemental composition โ particularly useful when surface treatments or coatings are a known source of extractables. A full Chemical & Elemental Characterization program typically integrates several of these techniques.
Comparison of Core Analytical Techniques in Extractables Study Design
| Technique | Target Chemical Class | Typical Detection Limit | Key Strength |
|---|---|---|---|
| GC-MS | Volatile & semi-volatile organics | Low ppb | Broad library identification |
| LC-MS/MS | Non-volatile & polar organics | Sub-ppb | High sensitivity for oligomers |
| ICP-MS / ICP-OES | Elemental impurities | Sub-ppb to ppt | Multi-element simultaneous analysis |
| NMR Spectroscopy | Unknown organic structures | Low ppm | Definitive structural elucidation |
| FTIR / Raman | Polymer and functional group ID | Bulk/surface | Rapid material screening |
| XRF / XPS | Surface elements & coatings | ppm (XRF); surface monolayers (XPS) | Non-destructive surface analysis |
Quick note: Many extractables study design failures stem not from poor analysis, but from inadequate study scoping at the planning stage. Defining material boundaries, solvent systems, extraction conditions, and AETs before any lab work begins is the most cost-effective investment a development team can make.
Comprehensive Chemical & Analytical Testing integrates these platforms into a single coordinated extractables program. This integration prevents data gaps and reduces turnaround time by running orthogonal techniques in parallel rather than sequentially. For complex materials, Scientific & Technical Consulting services help teams make defensible method and technique selection decisions before study initiation.
Additionally, Chemical Purity & Contaminant Screening capabilities support early-phase material qualification, where the goal is rapid identification of high-risk chemical species before committing to a full extractables program. For background on published analytical method strategies, ScienceDirect – Analytical Methods provides an extensive peer-reviewed resource base that study designers frequently consult.
How to Apply the Analytical Evaluation Threshold in Extractables Study Design
The Analytical Evaluation Threshold (AET) is the quantitative cornerstone of every extractables study design. It defines the minimum concentration at which a detected compound must be identified and reported. Consequently, the AET drives analytical method sensitivity requirements and instrument selection.
Teams calculate the AET from the permitted daily exposure (PDE) of a compound, the maximum daily dose of the product, and a safety factor. Specifically, a compound detected below the AET requires no further toxicological evaluation. However, any compound at or above the AET demands full identification, quantification, and toxicological assessment.
Calculating the AET for Your Product Type
AET calculation begins with the product’s clinical use parameters. These include the maximum daily dose volume, the number of doses per day, and the number of container components in contact with the drug. For instance, a low-dose injectable may produce a higher AET (less stringent detection requirement) than a high-volume infusion product administered repeatedly.
Furthermore, the calculation uses a default threshold of 0.1 ฮผg/day as the toxicological concern threshold (TTC) for unknown compounds, per ICH M7 principles adapted into extractables guidance. Therefore, analytical methods must reliably detect and quantify compounds at concentrations that correspond to the product-specific AET โ often in the low-ppb range.
Applying AET Across Multiple Solvent Systems
Each extraction solvent generates its own set of extract concentrations. Importantly, the AET applies to each solvent extract independently, adjusted for the extraction ratio used. Moreover, when multiple solvents are run in parallel, teams must track AET compliance separately for aqueous, organic, and acidic or basic extracts.
As a result, study planners often tabulate AET values for each solvent system before lab work begins. This table becomes a critical quality control document, guiding analysts on which peaks to report and which to discard as below threshold. Our Method Development & Validation team routinely assists clients in establishing and documenting these thresholds as part of the study protocol.
Industry-Specific Applications of Extractables Study Design
Extractables study design is not a one-size-fits-all discipline. The specific requirements shift substantially depending on the industry, product type, regulatory jurisdiction, and patient population involved. Understanding these differences is essential before finalizing any study protocol.
Moreover, some industries operate under overlapping regulatory frameworks, requiring study designers to satisfy multiple guidance documents simultaneously. In those cases, Scientific & Technical Consulting services help resolve conflicts and identify the most efficient path to compliance.
Pharmaceutical and Biologic Drug Products
Pharmaceutical programs typically follow ICH Q3E, ICH Q3D, USP <661>, USP <1663>, and USP <1664> guidance. Biologic drug products โ including monoclonal antibodies, gene therapies, and cell therapies โ face the most stringent extractables requirements. Specifically, even sub-ppb concentrations of certain extractables can destabilize protein structures or trigger immunogenic responses.
Therefore, extractables study design for biologics demands ultra-sensitive detection limits, extensive solvent coverage, and careful attention to oxidative and metal-ion extractables. Integrating Biocompatibility & Toxicity Testing data with the extractables chemical profile provides a complete safety picture for regulatory submission.
Medical Devices and Combination Products
Medical device programs operate primarily under ISO 10993-18 for chemical characterization. This standard requires a structured approach: material identification, chemical characterization, biological risk assessment, and clinical exposure estimation. Notably, combination products โ devices that contain a drug component โ must satisfy both pharmaceutical and device regulatory requirements simultaneously.
In addition, device materials often include multiple polymer types, adhesives, coatings, and metals. Each material class requires different extraction solvents and analytical platforms. Consequently, device extractables programs frequently run larger test matrices than pharmaceutical container-closure studies. Our published resource on medical device extractables and leachables details the device-specific regulatory and analytical landscape.
Aerospace, Industrial, and Environmental Applications
Beyond pharma and medical devices, extractables study design principles apply wherever material-chemical interactions affect safety or performance. Aerospace programs evaluate polymers, sealants, and coatings for outgassing behavior and chemical release under vacuum or elevated temperature conditions. Similarly, environmental programs assess extractables from plastic packaging, water treatment membranes, and food-contact materials.
Furthermore, industrial quality programs use extraction studies to qualify raw materials, detect counterfeit substances, and monitor supplier consistency. The Chemical & Analytical Testing capabilities at Materials Metric serve all of these sectors, applying the same rigorous extractables study design principles regardless of industry context.
Industry-Specific Study Design Requirements Comparison
| Industry | Primary Guidance | Key Driver | Typical AET Range |
|---|---|---|---|
| Pharmaceutical (small molecule) | ICH Q3E, USP <1663> | Patient safety / regulatory filing | Low ppb |
| Biologic / Biosimilar | ICH Q3E, USP <1663> | Protein stability / immunogenicity | Sub-ppb |
| Medical Device | ISO 10993-18 | Biocompatibility / CE / 510(k) | ppbโppm (contact-dependent) |
| Food Contact / Packaging | EU 10/2011, FDA 21 CFR | Consumer safety / compliance | ppmโppb |
| Aerospace / Industrial | NASA outgassing / ASTM E595 | Material performance / contamination control | Application-specific |
Quality Assurance and Best Practices in Extractables Study Design
Rigorous quality assurance practices distinguish a defensible extractables study from one that generates regulatory questions. Every element of the study โ from sample chain of custody to instrument calibration โ must be documented and traceable. Moreover, studies conducted under Good Laboratory Practice (GLP) conditions provide the highest level of regulatory confidence.
However, even non-GLP studies benefit significantly from systematic quality controls. Spike recovery experiments, method blanks, reagent blanks, and certified reference standards all contribute to data reliability. For background on published best practices, ScienceDirect hosts extensive peer-reviewed literature on analytical quality assurance methodologies.
Protocol Development and Change Control
A written extractables study protocol must be finalized and approved before sample preparation begins. This protocol locks in all critical parameters: sample identification, extraction conditions, solvent systems, analytical methods, acceptance criteria, and reporting thresholds. Importantly, any mid-study deviation requires documented justification and impact assessment.
Furthermore, change control procedures protect data integrity when equipment, reagents, or personnel change during a study. Consequently, teams that invest in thorough upfront protocol development avoid the costly and time-consuming amendment process. The Method Development & Validation framework at Materials Metric embeds these quality controls into every extractables program from day one.
Reference Standards and Spike Recovery
Reference standards are essential for compound identification and quantification accuracy. Specifically, certified reference materials allow analysts to confirm instrument response, validate retention times, and establish calibration curves across the working concentration range. Additionally, isotopically labeled internal standards โ used in ICP-MS and LC-MS/MS โ correct for matrix suppression effects and improve quantitative accuracy.
Spike recovery experiments verify that the extraction process and analytical workflow recover target analytes efficiently. Acceptable spike recovery typically falls between 70% and 130% for most extractables applications. As a result, poor spike recovery indicates a matrix interference or method problem that must be resolved before reporting study results. The Chemical & Elemental Characterization team at Materials Metric routinely applies these controls across all elemental and organic extractables programs.
Reporting, Documentation, and Regulatory Package Readiness
Study reports must present extractables data in a format that directly supports the safety risk assessment and regulatory submission. Typically, this means organized compound tables with chemical identity, CAS number, concentration, detection method, and AET comparison. Furthermore, chromatograms, spectra, calibration curves, and raw instrument data should be archived and available for regulatory inspection.
Additionally, USP Elemental Impurities guidance requires that elemental extractables data be traceable to specific container components and presented against established PDEs. Ultimately, a well-documented extractables study report functions as a standalone scientific document โ one that regulators can evaluate independently of the broader submission dossier.
Quick note: Regulatory reviewers frequently request raw data, instrument logs, and reference standard certificates during extractables data audits. Archiving these documents in a retrievable, organized format from day one โ not as an afterthought โ saves significant time during agency interactions.
Frequently Asked Questions About Extractables Study Design
What is the difference between extractables and leachables?
Extractables are chemicals released from a material under exaggerated laboratory conditions using aggressive solvents and elevated temperatures. Leachables, by contrast, are compounds that actually migrate into the drug product or patient under real-use conditions. Consequently, extractables studies generate a worst-case chemical inventory, while leachables studies confirm what actually transfers in practice. Our article on extractables vs leachables provides a detailed breakdown of this distinction.
When should an extractables study design be initiated?
Ideally, extractables study design begins during early-stage material selection โ well before the drug product formulation or device design is locked. Starting early allows teams to reject high-risk materials before significant development investment occurs. Moreover, early extractables data supports informed decisions about container-closure system changes, supplier qualification, and formulation compatibility.
How many solvents does a typical extractables study require?
Most regulatory guidance recommends a minimum of three extraction solvents covering a range of polarity: an aqueous solvent, an organic solvent, and an acidic or basic medium. However, more complex materials โ such as multi-layer films or silicone-based medical device components โ may require four to six solvents to adequately cover all chemical classes present. Additionally, simulated drug product formulations are sometimes included as a fourth extraction medium.
What analytical techniques are most commonly used in extractables studies?
The most widely used techniques include GC-MS Analysis for volatile and semi-volatile organics, HPLC Analysis (LC-MS/MS) for non-volatile polar compounds, and ICP-MS or ICP-OES for elemental impurities. Furthermore, NMR Spectroscopy and FTIR Analysis support structural confirmation of unknown compounds. The specific technique combination depends on the material type, product application, and regulatory pathway.
Does an extractables study need to be conducted under GLP conditions?
GLP compliance is not universally required for extractables studies, but it is often expected for studies supporting regulatory submissions in high-risk product categories. Specifically, studies submitted as part of an NDA, BLA, or PMA application benefit from GLP rigor, which provides auditable documentation and enhanced regulatory credibility. Nevertheless, even non-GLP studies must follow robust quality controls to produce scientifically defensible data.
How does extractables study design support leachables risk assessment?
The extractables chemical inventory serves as the predicted leachables list. Toxicologists use this list to prioritize which compounds require formal safety qualification if they appear in the drug product. Specifically, compounds identified above the AET in extraction studies become candidates for leachables monitoring in real-use samples. Therefore, a comprehensive extractables study design directly reduces the scope of uncertainty in the downstream leachables and safety evaluation process.
Conclusion
A rigorous extractables study design is the scientific and regulatory foundation that supports every downstream safety assessment, leachables program, and regulatory submission. Getting the design right โ from scope definition and solvent selection to AET calculation and analytical method coverage โ determines whether a product advances confidently through development or encounters costly delays.
Furthermore, the field continues to evolve as new materials, biologic drug formats, and regulatory guidance documents emerge. Consequently, study designers must stay current with ICH, ISO, and USP updates while applying fit-for-purpose analytical strategies that match the specific risk profile of each product. The investment in a well-constructed extractables study design repays itself many times over by preventing late-stage surprises.
Moreover, partnering with an experienced analytical laboratory ensures that your extractables program integrates the right techniques, applies correct thresholds, and produces documentation that regulators accept with confidence. From early material screening through final submission support, the team at Materials Metric delivers coordinated extractables programs across pharmaceutical, medical device, and industrial sectors.
If your team is planning an extractables program โ or needs to rescue a study with data gaps โ contact Materials Metric today to discuss your specific materials, product type, and regulatory requirements with our analytical and regulatory specialists.
Related Posts from Materials Metric
Explore more insights from our team of materials scientists and analytical experts:
